aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding aTYR PHARMA INC changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 41 | 46 | +5 |
| Shares | 36.7M | 41.2M | +4.52M (+12.3%) |
| Value | $58.7M | $58.1M | −$543.0K (−0.9%) |
New holders (9)
Institutions that held aTYR PHARMA INC at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 5,850,000 | $8.25M | 0.92% |
| Checkpoint Capital L.P. | 1,503,554 | $2.12M | 1.48% |
| Goldman Sachs Group Inc | 143,570 | $202.4K | 0.00% |
| Barclays PLC | 78,972 | $111.4K | 0.00% |
| Citigroup Inc | 78,620 | $110.9K | 0.00% |
| Farther Finance Advisors, LLC | 30,323 | $42.8K | 0.00% |
| Acadian Asset Management LLC | 20,662 | $29.0K | 0.00% |
| Granite Bay Wealth Management, LLC | 18,000 | $22.0K | 0.00% |
| Prudential Financial Inc | 15,200 | $21.4K | 0.00% |
Sold out (4)
Institutions that held aTYR PHARMA INC at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Man Group plc | – | $665.7K |
| Boothbay Fund Management, LLC | 36,000 | $56.9K |
| Simplex Trading, LLC | 9,032 | $14.0K |
| Tower Research Capital LLC (TRC) | 682 | $1.08K |